Article and Video CATEGORIES
Dr. Ravi Salgia on Management Strategies for Acquired Resistance to Targeted Therapies, Single Focus or More Diffuse
Dr. Ravi Salgia from University of Chicago explains his approach to management of acquired resistance to a targeted therapy for advanced NSCLC, both in the setting of a single area of progression and also when disease progression is more diffuse.
[powerpress]
Please feel free to offer comments and raise questions in our
discussion forums.
Forum Discussions
Can SCLC also be treated with targeted therapy?
Hi amitchouhan,
Welcome to Grace. At this time, there aren't any targeted therapies to treat SCLC, but there are new treatments. Check out our latest OncTalk webinar from December. The last...
I was searching for this, Thank you so much for the info.
Recent Comments
Yes, it's crucial to discuss…
By JanineT GRACE … on
Definitely a good idea to…
By OakleeFarnick on